About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

I think he might win as top Ramper for the year !! IanT moneyam vote thread

anyone know why ACV is rocketing

Not wishing to malign innocent MM's but, probably manipulation by at least 1 of them PH! A cash shell company with not a lot left to brag about. They could get lucky, but I would rather top up with ERX than buy into ACV. (Not a ramp, just my preference!)
kim

ACV because of yesterdays news the problem is punters have been waiting for years for a positive proposal.

"The board said it looks forward to reporting further with a positive proposal".

Is PH on the board Driver ;-)
kim

kim
PH hasn't got any ACV his on a wind up.

I am in a state of shock Driver! :oD
kim

;-).. if only i hadnt bought some yesterday eh!!!

Does anyone know when in December there results are due?

PH
There was only an 80,242 @ .0013 104 trade yesterday perhaps you are not the big boy we all thought you was.

;-)

Also this morning ;-)

Advance Visual Communicaitons evaluating number of investments
LONDON (AFX) - Advance Visual Communications PLC, which has now completed
the process of disposing of all its interests in the subsidiaries formerly held,
said it is evaluating a number of investments.
The group today reported a loss before and after tax of 69,500 stg for the
year to June 30 2006.
It said cash balances at the period end were 25,431 stg, adding that it is
endeavouring to minimize the cash outflow.
The board said it looks forward to reporting further with a positive
proposal.



IN WHAT WAY CAN THEY OFFER ANYTHING POSSITIVE

;-)

ph you ok, see your geting a hard time over on the dark side, : )

Well I wanted a bit of company ;-)

Pipeline update from OSI pharma re ERX tomorrow, and MGI pharma pipeline update re ERX ZYC300 on wednesday

cant wait!!!

Bio-IT Briefs November 27, 2006 | The National Library of Medicine (NLM), a part of the National Institutes of Health (NIH), is awarding 18 five-year grants, totaling more than $75million, for research training in biomedical informatics, the discipline that seeks to apply computer and communications technology to the field of health. For more than 30 years, NLM has been the primary sponsor of biomedical informatics research training in the United States. At its current group of 18 informatics programs, NLM supports nearly 300 pre-doctoral and post-doctoral trainees each year. Trainees come to these programs with a range of educational and professional backgrounds; the group includes physicians, biologists, computer scientists, and engineers. Read the press release.

Artemis Pharmaceuticals GmbH has signed a research agreement with Merck & Co. Inc. to construct a large number of shRNA interference ("shRNAi ") - genetically engineered mouse models for the in vivo functional analysis of selected disease related genes. The agreement represents a significant initiative to undertake a large-scale approach to gene function analysis using shRNA knock down in genetically engineered mice as models for human biology. Under the terms of the agreement, Artemis will generate genetically engineered shRNAi "knock down" mouse models for Merck using Artemis' proprietary, optimized and fully integrated vector construction, ES cell transfection and inducible RNAi technology. Merck will provide selected shRNA sequences that correspond to mouse genes that may also play a central role in human diseases. Artemis will use its technologies to achieve constitutive as well as inducible functional down-regulation of the expression of the gene targets provided by Merck. Read the press release.

Kendle, a Cincinnati-based clinical research organization, has appointed Sylva Collins as vice president of global biometrics. Collins formerly ran electronic data management for Novartis, managing more than 400 EDC studies approximately 130,000 patients worldwide. She will oversee Kendles global Biometrics services, including clinical data management, biostatistics and scientific programming. Website: www.kendle.com.

Agilent Technologies has launched a new product demonstration center at its Santa Clara, Calif., corporate headquarters, showcasing its life sciences and chemical analysis capabilities. The Center of Excellence launch follows the recent opening of a similar center in Bangalore, India, and recent expansions of Agilent product demonstration centers in Paris, France; Manchester, U.K.; and Waldbronn, Germany. Planned for late 2007 is yet another center in Little Falls, Delaware. Read the press release

exciting day tomorrow

what makes you so confident PH